[go: up one dir, main page]

MA34554B1 - Combinaisons pharmaceutiques - Google Patents

Combinaisons pharmaceutiques

Info

Publication number
MA34554B1
MA34554B1 MA35783A MA35783A MA34554B1 MA 34554 B1 MA34554 B1 MA 34554B1 MA 35783 A MA35783 A MA 35783A MA 35783 A MA35783 A MA 35783A MA 34554 B1 MA34554 B1 MA 34554B1
Authority
MA
Morocco
Prior art keywords
combination
mtor
treatment
kinase
simultaneous
Prior art date
Application number
MA35783A
Other languages
English (en)
Inventor
Yan Chen
Xizhong Huang
Leon Murphy
Beat Nyfeler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44802399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34554(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34554B1 publication Critical patent/MA34554B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une combinaison pharmaceutique qui comprend (a) un inhibiteur catalytique de mTOR, tel qu'une phosphatidylinositol-3-kinase (PI3K) catalytique et un composé inhibiteur de mTOR qui est un dérivé d'imidazoquinoline et (b) au moins un composé allostérique inhibiteur de mTOR, et éventuellement, au moins un vecteur pharmaceutiquement acceptable, pour une utilisation simultanée, séparée ou séquentielle, en particulier pour le traitement d'une cible mammifère de maladies de prolifération dépendantes de la rapamycine (mTOR) kinase ; et les utilisations d'une telle combinaison dans le traitement de maladies de prolifération dépendantes de la mTOR kinase ; une composition pharmaceutique comprenant une telle combinaison ; l'utilisation d'une telle combinaison pour la préparation d'un médicament pour le traitement d'une maladie de prolifération ; un conditionnement ou produit commercial comprenant une telle combinaison en tant que préparation combinée pour une utilisation simultanée, séparée ou séquentielle ; et une méthode de traitement d'un animal à sang chaud, en particulier un être humain.
MA35783A 2010-10-04 2011-10-03 Combinaisons pharmaceutiques MA34554B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38944510P 2010-10-04 2010-10-04
PCT/US2011/054536 WO2012047775A1 (fr) 2010-10-04 2011-10-03 Combinaisons pharmaceutiques

Publications (1)

Publication Number Publication Date
MA34554B1 true MA34554B1 (fr) 2013-09-02

Family

ID=44802399

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35783A MA34554B1 (fr) 2010-10-04 2011-10-03 Combinaisons pharmaceutiques

Country Status (21)

Country Link
US (1) US20130178479A1 (fr)
EP (1) EP2624831A1 (fr)
JP (1) JP2013538876A (fr)
KR (1) KR20130108330A (fr)
CN (1) CN103153305A (fr)
AR (1) AR083267A1 (fr)
AU (1) AU2011312372A1 (fr)
BR (1) BR112013008074A2 (fr)
CA (1) CA2812786A1 (fr)
CL (1) CL2013000895A1 (fr)
CO (1) CO6710908A2 (fr)
EC (1) ECSP13012541A (fr)
MA (1) MA34554B1 (fr)
MX (1) MX2013003833A (fr)
NZ (1) NZ608375A (fr)
PE (1) PE20140203A1 (fr)
PH (1) PH12013500581A1 (fr)
RU (1) RU2013120357A (fr)
SG (1) SG188521A1 (fr)
TW (1) TW201217374A (fr)
WO (1) WO2012047775A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
EP2675450B1 (fr) * 2011-02-16 2016-02-10 Novartis AG Combinaisons d'agents thérapeutiques pour une utilisation dans le traitement de maladies neurodégénératives
WO2013192367A1 (fr) * 2012-06-22 2013-12-27 Novartis Ag Traitement d'une tumeur neuroendocrine
WO2014028566A1 (fr) * 2012-08-16 2014-02-20 Novartis Ag Combinaison d'un inhibiteur pi3k et d'un inhibiteur c-met
JO3377B1 (ar) * 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
MX2017014776A (es) 2015-05-20 2018-02-15 Novartis Ag Combinacion farmaceutica de everolimus con dactolisib.
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
EP3544608A1 (fr) 2016-11-23 2019-10-02 Novartis AG Méthodes d'amélioration de la réponse immunitaire à l'évérolimus, au dactolisib ou aux deux
WO2019157516A1 (fr) 2018-02-12 2019-08-15 resTORbio, Inc. Polythérapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101360495B (zh) * 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
CN101616672A (zh) * 2007-02-20 2009-12-30 诺瓦提斯公司 作为脂质激酶和mTOR双重抑制剂的咪唑并喹啉类

Also Published As

Publication number Publication date
WO2012047775A1 (fr) 2012-04-12
CA2812786A1 (fr) 2012-04-12
CO6710908A2 (es) 2013-07-15
JP2013538876A (ja) 2013-10-17
KR20130108330A (ko) 2013-10-02
MX2013003833A (es) 2013-06-28
BR112013008074A2 (pt) 2016-06-14
RU2013120357A (ru) 2014-11-20
ECSP13012541A (es) 2013-06-28
SG188521A1 (en) 2013-04-30
AU2011312372A1 (en) 2013-04-04
EP2624831A1 (fr) 2013-08-14
PH12013500581A1 (en) 2013-05-20
CN103153305A (zh) 2013-06-12
TW201217374A (en) 2012-05-01
NZ608375A (en) 2014-08-29
PE20140203A1 (es) 2014-02-28
CL2013000895A1 (es) 2013-09-27
US20130178479A1 (en) 2013-07-11
AR083267A1 (es) 2013-02-13

Similar Documents

Publication Publication Date Title
MA34554B1 (fr) Combinaisons pharmaceutiques
JP7054691B2 (ja) 表皮水疱症及び関連する結合組織疾患の治療におけるカンナビノイドの局所製剤の使用
RU2745678C2 (ru) Способы лечения рака
Dubar et al. Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach
Lee et al. Endothelial progenitor cells in cardiovascular diseases
Xie et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy
Thomas et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo
Olesch et al. MPGES-1-derived PGE2 suppresses CD80 expression on tumor-associated phagocytes to inhibit anti-tumor immune responses in breast cancer
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
JP2022034068A (ja) 非ｅｒｋ ｍａｐｋ経路阻害剤耐性のがんを処置するための方法および組成物
MA32458B1 (fr) Combinaison d'un antagoniste de c-met et d'un compose aminoheteroaryle pour le traitement d'un cancer
Huang et al. Fisetin attenuates periodontitis through FGFR1/TLR4/NLRP3 inflammasome pathway
Tarantelli et al. Copanlisib synergizes with conventional and targeted agents including venetoclax in B-and T-cell lymphoma models
MA39040A1 (fr) Nouveau traitement combiné pour la leucémie aiguë myéloïde (lam)
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
WO2009058895A1 (fr) Administration d'un inhibiteur de hdac et d'un inhibiteur de mtor
WO2009126662A1 (fr) Administration d'un inhibiteur de hdac, d'un inhibiteur de her-2, et d'un modulateur du récepteur de l'œstrogène sélectif
WO2017042944A1 (fr) Agent thérapeutique ou méthode de traitement pour la leucémie lymphoïde aiguë (lla) à chromosome philadelphie positif (ph+)
WO2009046436A1 (fr) Procédés pour inhiber la sénescence des cellules épithéliales
CA2977298A1 (fr) Procede pour le traitement des cancers primitifs de l'endometre et du sein resistants aux hormones
WO2022200339A1 (fr) Traitement de l'hidradénite suppurée avec de l'orismilast
Mirkheshti et al. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer
Göbel et al. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins
MA35363B1 (fr) Utilisation d'un composé organisation dans le traitement du syndrome de noonan